2-Imino-4-methylpiperidine (acetate)
(Synonyms: 2-亚氨基-4-甲基哌啶乙酸酯) 目录号 : GC17084
A potent, general NOS inhibitor
Cas No.:165383-72-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2-Imino-4-methylpiperidine (acetate) is a potent NOS inhibitor [1]
Nitric oxide (NO) is an endogenously produced inorganic free radical gas which has been implicated in endothelium-dependent vascular relaxation, cell-to-cell communication, and cytotoxicity associated with phagocytic cells. NO is synthesized by three isoforms of nitric oxide synthase (NOS): nNOS, eNOS and iNOS [1].
2-Imino-4-methylpiperidine (acetate) is a 2-iminopiperidine class of NOS inhibitor. In the presence of a final L-arginine concentration of 30 μM, 2-Imino-4-methylpiperidine inhibited human iNOS, eNOS, and nNOS with IC50 values of 0.1, 1.1, and 0.2 μM, respectively. 2-Imino-4-methylpiperidine exhibited 9-fold and 1-fold selectivity for iNOS compared to eNOS and nNOS, respectively [1].
In LPS-treated rats, 2-Imino-4-methylpiperidine (10 mg/kg, po) inhibited plasma nitrite levels by 87%.
Reference:
[1]. Webber RK, Metz S, Moore WM, et al. Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1998 Jan 1;41(1):96-101.
| Cas No. | 165383-72-2 | SDF | |
| 别名 | 2-亚氨基-4-甲基哌啶乙酸酯 | ||
| 化学名 | 3,4,5,6-tetrahydro-4-methyl-2-pyridinamine, acetate | ||
| Canonical SMILES | CC1CCN=C(N)C1.CC([O-])=O | ||
| 分子式 | C6H12N2 · C2H3O2 | 分子量 | 171.2 |
| 溶解度 | ≤5mg/ml in ethanol;5mg/ml in DMSO;5mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.8411 mL | 29.2056 mL | 58.4112 mL |
| 5 mM | 1.1682 mL | 5.8411 mL | 11.6822 mL |
| 10 mM | 0.5841 mL | 2.9206 mL | 5.8411 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。